Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?

Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs.  Novo Nordisk got off to an early lead, but Eli Lilly is now the most noted name in the space.